Trabectedin



Trabectedin
Systematic (IUPAC) name
(1'R,6R,6aR,7R,13S,14S,16R)-6',8,14-trihydroxy-
7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,
12,13,14,16-octahydrospiro[6,16-(epithiopropano
oxymethano)-7,13-imino-6aH-1,3-dioxolo[7,8]isoquino
[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-5-yl acetate
Identifiers
CAS number 114899-77-3
ATC code L01CX01
PubChem 108150
Chemical data
S 
Mol. mass 761.84 g/mol
Pharmacokinetic data
Bioavailability Not applicable (IV only)
Protein binding 94 to 98%
CYP3A4-mediated)
Half life 180 hours (mean)
Excretion Mostly fecal
Therapeutic considerations
Licence data

EU 

Pregnancy cat.

?

Legal status
Routes Intravenous

Trabectedin (also known as ecteinascidin 743 or by the brand name Yondelis) is a experimental anti-tumor drug. First isolated from aqueous Elias James Corey in 1996.

Synthesis

Biosynthesis is also beleieved to involve the dimerization of two Ugi reaction to assist in the formation of the pentacyclic core. This reaction was unprecedented for using such a one pot multi-component reaction in the synthesis of such a complex molecule.

Mechanism of action

The biological oxazolidine form.

 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Trabectedin". A list of authors is available in Wikipedia.